• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket

    12/20/23 8:30:58 AM ET
    $ACON
    $ARGX
    $AUVI
    $BLUE
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACON alert in real time by email

    Shares of Aclarion, Inc. (NASDAQ:ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS (Severe Low Back Pain)."

    Aclarion shares jumped 53.1% to $0.4480 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • AEye, Inc. (NASDAQ:LIDR) rose 28.4% to $0.0904 in pre-market trading. AEyer shares fell around 30% on Tuesday after representatives of Continental informed the company that it intends to discontinue the parties' joint lidar development program, which includes further development of the HRL131 lidar product line.
    • Applied UV, Inc.(NASDAQ:AUVI) gained 26.7% to $2.32 in pre-market trading after jumping around 21% on Tuesday. Applied UV recently announced successful integration of its PURO UV disinfection and airocide food preservation units to optimize cost reduction and expand global growth opportunities.
    • U Power Limited (NASDAQ:UCAR) shares climbed 18.2% to $0.2450 in pre-market trading after declining around 15% on Tuesday. U Power recently announced pricing of its registered follow-on offering.
    • Regional Health Properties, Inc. (NYSE:RHE) shares gained 16.3% to $2.50 in pre-market trading after falling around 9% on Tuesday. The company, last month, posted a narrower loss for the third quarter.
    • Polished.com Inc. (NYSE:POL) shares surged 16.1% to $1.23 in pre-market trading after falling 12% on Tuesday. The company, last month, posted a wider third-quarter loss.
    • Beyond Air, Inc. (NASDAQ:XAIR) shares gained 14.7% to $1.95 in pre-market trading. Beyond Air, Director Robert Carey, reported the purchase of 1.2 million shares at an average price of $1.635 per share in Form 4 filing on Tuesday.
    • PLBY Group, Inc. (NASDAQ:PLBY) shares rose 12.9% to $0.85 in pre-market trading after gaining 5% on Tuesday. PLBY Group, last month, reported worse-than-expected third-quarter EPS results.
    • Secoo Holding Limited (NASDAQ:SECO) shares rose 12% to $0.7919 in pre-market trading after jumping 41% on Tuesday.
    • Northann Corp. (NYSE:NCL) gained 11.1% to $2.00 in pre-market trading after dipping 88% on Tuesday.

    Losers

    • Rezolute, Inc. (NASDAQ:RZLT) shares fell 59.6% to $0.3568 in pre-market trading. Rezolute recently said it has initiated sunRIZE Phase 3 study of RZ358 in patients with congenital hyperinsulinism.
    • bluebird bio, Inc. (NASDAQ:BLUE) shares fell 30.4% to $1.69 in pre-market trading. bluebird bio priced $125 million public offering of 83,333,333 common shares at $1.50 per share.
    • argenx SE (NASDAQ:ARGX) shares fell 30.4% to $314.86 in pre-market trading after the company disclosed topline results from the ADDRESS study evaluating efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus.
    • Nogin, Inc. (NASDAQ:NOGN) fell 25.8% to $0.12 in pre-market trading after surging 42% on Tuesday.
    • Vast Renewables Limited (NASDAQ:VSTE) fell 20.9% to $9.48 in pre-market after dipping 14% on Tuesday.
    • Xilio Therapeutics, Inc. (NASDAQ:XLO) fell 20.7% to $0.4768 in pre-market trading after dipping over 16% on Tuesday.
    • KULR Technology Group, Inc. (NASDAQ:KULR) shares fell 18.7% to $0.2407 in pre-market trading after announcing a proposed public offering of common stock.
    • Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 17.7% to $1.29 in pre-market trading after jumping 55% on Tuesday. The company recently announced FDA approval of eflornithine, a drug they divested to US WorldMeds, for treating high-risk neuroblastoma patients who responded partially to prior therapies.
    • Steelcase Inc. (NYSE:SCS) shares fell 10.2% to $11.41 in pre-market trading. Steelcase posted upbeat earnings for its third quarter, while sales missed estimates. The company said it sees fourth-quarter adjusted earnings of 19 cents to 23 cents per share on revenue of $765 million to $790 million.
    • FedEx Corporation (NYSE:FDX) shares fell 9.6% to $253.10 in pre-market trading after the company posted weaker-than-expected earnings for its second quarter and lowered its full-year revenue outlook.

     

    Now Read This: FedEx, General Mills And 3 Stocks To Watch Heading Into Wednesday

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ARGX
    $AUVI
    $BLUE

    CompanyDatePrice TargetRatingAnalyst
    argenx SE
    $ARGX
    3/10/2026Hold → Buy
    Deutsche Bank
    FedEx Corporation
    $FDX
    2/25/2026$335.00Hold → Reduce
    HSBC Securities
    FedEx Corporation
    $FDX
    2/13/2026$313.00 → $383.00Buy
    TD Cowen
    FedEx Corporation
    $FDX
    2/3/2026$380.00Equal Weight → Overweight
    Wells Fargo
    FedEx Corporation
    $FDX
    2/3/2026$427.00Mkt Perform → Outperform
    Bernstein
    FedEx Corporation
    $FDX
    1/21/2026$271.00Buy → Neutral
    Rothschild & Co Redburn
    FedEx Corporation
    $FDX
    1/13/2026$280.00Outperform → Neutral
    BNP Paribas Exane
    FedEx Corporation
    $FDX
    1/9/2026$365.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ACON
    $ARGX
    $AUVI
    $BLUE
    SEC Filings

    View All

    SEC Form 20-F filed by argenx SE

    20-F - ARGENX SE (0001697862) (Filer)

    3/19/26 6:13:02 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    3/19/26 6:05:34 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by U Power Limited

    EFFECT - U Power Ltd (0001939780) (Filer)

    3/19/26 12:15:38 AM ET
    $UCAR
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    U Power Limited Announces Pricing of $6.0 Million Public Offering

    SHANGHAI, March 19, 2026 /PRNewswire/ -- U Power Limited (NASDAQ:UCAR) (the "Company" or "U Power"), a provider of AI-integrated solutions for next-generation energy grids and intelligent transportation systems, today announced the pricing of an underwritten public offering of 13,360,000 Units, on a firm commitment basis, at a price to the public of $0.449 per Unit.  Each Unit consists of one Class A ordinary share, par value $0.00001 per share (each, a "Class A Ordinary Share," and collectively, the "Class A Ordinary Shares"), and one Class A warrant (each, a "Warrant," and collectively, the "Warrants"). Each Warrant will expire one year from the date of issuance, and is exercisable immedia

    3/19/26 8:45:00 AM ET
    $UCAR
    Auto Parts:O.E.M.
    Consumer Discretionary

    Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

    Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's

    3/19/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    argenx upgraded by Deutsche Bank

    Deutsche Bank upgraded argenx from Hold to Buy

    3/10/26 3:28:52 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FedEx downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded FedEx from Hold to Reduce and set a new price target of $335.00

    2/25/26 11:18:50 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    TD Cowen reiterated coverage on FedEx with a new price target

    TD Cowen reiterated coverage of FedEx with a rating of Buy and set a new price target of $383.00 from $313.00 previously

    2/13/26 8:02:23 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:18:04 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:16:14 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Elam Nevan C covered exercise/tax liability with 27,618 shares, decreasing direct ownership by 4% to 613,501 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:07:36 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ARGX
    $AUVI
    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Leadership Updates

    Live Leadership Updates

    View All

    Playboy Appoints David Miller as President, Media & Brand

    Media Veteran Miller to Oversee Global Licensing, Digital and Platform Growth Senior Appointment Reflects Playboy's Accelerating Growth Strategy and Expanding Media and Licensing Operations LOS ANGELES, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ:PLBY) ("Playboy" or the "Company"), a global pleasure and leisure company, has announced that David Miller has been appointed President, Media & Brand, to drive the next phase of the Company's growth. Miller joins Playboy from The Walt Disney Company, where he served as Executive Vice President and General Manager of National Geographic Media, with full P&L responsibility across global editorial, digital, print, and social operation

    2/26/26 8:31:00 AM ET
    $PLBY
    Other Specialty Stores
    Consumer Discretionary

    FedEx Appoints Scott Ray as Chief Operating Officer for U.S. and Canada Surface Operations

    FedEx Corp. (NYSE:FDX) today announced the appointment of Scott Ray as chief operating officer for U.S. and Canada Surface Operations, effective June 1. He will begin transitioning into the role as COO-elect on Feb. 1. Reporting to FedEx President and CEO Raj Subramaniam, Ray will be the newest member of the FedEx Executive Committee, succeeding John Smith, who will transition to CEO of FedEx Freight as of June 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126094399/en/FedEx appoints Scott Ray as chief operating officer of Surface Operations in U.S. and Canada Ray will be responsible for leading all aspects of Surface Ope

    1/27/26 8:31:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    FedEx Announces Board of Directors for Future Independent FedEx Freight

    Board includes veteran leaders with transportation and logistics, financial, and technology expertise FedEx Corp. (NYSE:FDX) today announced the ten-member board of directors for FedEx Freight, ahead of its planned spin-off from FedEx Corp. on June 1, 2026. As previously announced, R. Brad Martin, current executive chairman of the FedEx Corp. board of directors, will serve as chairman of the board of FedEx Freight. John Smith, the incoming president and chief executive officer of FedEx Freight, will also serve as a director, alongside eight other highly experienced leaders across the transportation and logistics, supply chain management, and technology sectors. "We've assembled a grou

    1/16/26 8:01:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Financials

    Live finance-specific insights

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    AEye Reports Fourth Quarter and Full-Year 2025 Results; Strengthened Foundation for Commercial Growth

    Revenue Doubled in Q4 over Q3; 40% Commercial Pipeline Expansion; 33% Increase in Customer Count Joining NVIDIA Halos AI Systems Inspection Lab; Demonstrated Apollo™ Lidar with NVIDIA DRIVE AGX Thor™ Operational Runway Into 2028 AEye, Inc. (NASDAQ:LIDR) (the "Company"), a global leader in software-defined, high-performance lidar solutions, today announced financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights NVIDIA Ecosystem Maturity: Joining NVIDIA Halos AI Systems Inspection Lab to bolster automotive product readiness and demonstrated Apollo™ lidar with the NVIDIA DRIVE AGX Thor™ platform, the future centralized brain of NVIDIA-equi

    3/16/26 4:35:00 PM ET
    $LIDR
    Auto Parts:O.E.M.
    Consumer Discretionary

    Playboy Reports Fourth Quarter and Full Year 2025 Financial Results

    LOS ANGELES, March 16, 2026 (GLOBE NEWSWIRE) -- Playboy, Inc. (NASDAQ:PLBY) (the "Company" or "Playboy"), a global pleasure and leisure company connecting consumers with products, content, and experiences that help them lead happier, more fulfilling lives, today announced financial and operational results for the fourth quarter and full year ended December 31, 2025. Financial Summary ($ in millions)Q4 2025Q4 2024% ChangeRevenues$34.9$33.54%Operating Expenses$(32.2)$(37.9)(15)%Net Income (Loss)$3.6$(12.5)129%Adj. EBITDA (non-GAAP)$7.1$(0.1)7200% Fourth Quarter 2025 & Recent Operational Highlights: Licensing revenue remains highly predictable and recurring, with 90% of fiscal year 2025 lic

    3/16/26 4:05:00 PM ET
    $PLBY
    Other Specialty Stores
    Consumer Discretionary

    $ACON
    $ARGX
    $AUVI
    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

    11/14/24 4:39:36 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care